Pembrolizumab before surgery for advanced head and neck cancer
Part of Cancer clinical trials.
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 85 years old
- You have head and neck squamous cell cancer that has not spread to distant parts (stage III or IV A), with the right cancer locations
- You have not received treatment for this cancer yet (other than a diagnostic biopsy)
- Your health status is fairly good (ECOG 0 or 1) and your doctor thinks you should have standard surgery plus standard chemo-radiation or radiation afterward
- You do NOT have certain immune problems: no active autoimmune disease and no active infections that need treatment right now
- Your blood counts and organ function are within required ranges for liver, kidneys, and blood cells
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
This Phase 2 trial tests pembrolizumab and an investigational drug (IO102-103) given before surgery for certain non-bulky head and neck squamous cell cancers. The goal is to shrink the cancer and improve chances of cure by treating it before the operation.
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.